Background: There are chronic forms of hypersensitivity pneumonitis (cHP) that can progress to pulmonary fibrosis. There is no recommended treatment for patients whose respiratory condition continues to deteriorate in spite of antigen avoidance. Whether rituximab may be beneficial to patients with cHP is unknown. The aim of this study was to...
-
October 2020 (v1)Journal articleUploaded on: December 4, 2022
-
June 1, 2021 (v1)Journal article
BACKGROUND: Chronic lung allograft dysfunction (CLAD) and its obstructive form, the obliterative bronchiolitis (OB), are the main long-term complications related to high mortality rate postlung transplantation. CLAD treatment lacks a significant success in survival. Here, we investigated a new strategy through inhibition of the proinflammatory...
Uploaded on: December 3, 2022 -
May 25, 2023 (v1)Journal article
Background Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first step therapies while rituximab is used as rescue therapy. Methods In a randomised, double blind, two-parallel group, placebo-controlled trial ( NCT02990286 ), patients...
Uploaded on: June 3, 2023